Literature DB >> 19239677

Reversible cerebral vasoconstriction syndrome: a complicated clinical course treated with intra-arterial application of nimodipine.

M Elstner1, J Linn, S Müller-Schunk, A Straube.   

Abstract

Thunderclap headache (TCH) is a neurological emergency that warrants immediate and comprehensive diagnostic determination. When no pathology can be identified the condition is classified as primary TCH, which is considered benign and self-limiting. TCH has also been reported as the initial symptom of reversible cerebral vasoconstriction syndrome (RCVS), which subsumes a variety of conditions, inconsistently coined Call-Flemming syndrome, benign angiopathy of the central nervous system, drug-induced arteritis, or migrainous vasospasm. Serious complications such as borderline ischaemic stroke have been reported. Although no standardized treatment regime exists, one commonly described but unproven therapy is parenteral or oral application of the calcium channel blocker nimodipine. Here, we report on a case of RCVS, where a progressive course prompted intra-arterial application of nimodipine, which resolved vasoconstriction immediately. We discuss the use of intra-arterial nimodipine application as a potential emergency treatment for a complicated or treatment-refractory course of RCVS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19239677     DOI: 10.1111/j.1468-2982.2008.01768.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  20 in total

1.  55-Year-old man with thunderclap headache.

Authors:  Srijana Zarkou; Esma Dilli; David W Dodick
Journal:  Mayo Clin Proc       Date:  2010-07       Impact factor: 7.616

2.  Intra-Arterial Verapamil Treatment in Oral Therapy-Refractory Reversible Cerebral Vasoconstriction Syndrome.

Authors:  J M Ospel; C H Wright; R Jung; L L M Vidal; S Manjila; G Singh; D V Heck; A Ray; K A Blackham
Journal:  AJNR Am J Neuroradiol       Date:  2019-12-26       Impact factor: 3.825

Review 3.  Reversible cerebral vasoconstriction syndrome: a review of recent research.

Authors:  Arnaldo Velez; James S McKinney
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

4.  Fulminant Reversible Cerebral Vasoconstriction Syndrome.

Authors:  Kushak Suchdev; Gregory Norris; Imad Zak; Wazim Mohamed; Mohammed Ibrahim
Journal:  Neurohospitalist       Date:  2017-01-01

Review 5.  Abrupt-onset severe headaches.

Authors:  Yo-El S Ju; Todd J Schwedt
Journal:  Semin Neurol       Date:  2010-03-29       Impact factor: 3.420

Review 6.  Reversible cerebral vasospasm, multilobular intracerebral hemorrhages, and nonaneurysmal subarachnoid hemorrhage: review of possible interrelationships.

Authors:  Philippe Hantson; Patrice Forget
Journal:  Curr Pain Headache Rep       Date:  2010-06

7.  Quantifying Intra-Arterial Verapamil Response as a Diagnostic Tool for Reversible Cerebral Vasoconstriction Syndrome.

Authors:  J M Sequeiros; J A Roa; R P Sabotin; S Dandapat; S Ortega-Gutierrez; E C Leira; C P Derdeyn; G Bathla; D M Hasan; E A Samaniego
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-17       Impact factor: 3.825

8.  Reversible cerebral vasoconstriction syndrome: an under-recognized clinical emergency.

Authors:  Shih-Pin Chen; Jong-Ling Fuh; Shuu-Jiun Wang
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

Review 9.  Reversible cerebral vasoconstriction syndrome: a comprehensive update.

Authors:  Ali Mehdi; Rula A Hajj-Ali
Journal:  Curr Pain Headache Rep       Date:  2014-09

10.  Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome.

Authors:  Aneesh B Singhal; Mehmet A Topcuoglu
Journal:  Neurology       Date:  2016-12-09       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.